Inhibikase Therapeutics (IKT) Other financing activities (2020 - 2025)

Inhibikase Therapeutics (IKT) has reported Other financing activities for 4 consecutive years, with $562915.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Other financing activities changed N/A year-over-year to $562915.0; the TTM figure through Dec 2025 stood at $813847.0 (changed N/A YoY), while the FY2025 annual figure was $845468.0, changed N/A from the prior year.
• Other financing activities climbed to $562915.0 in Q4 2025 per IKT's latest filing, from $250932.0 in the prior quarter.
• Across five years, Other financing activities topped out at $41.1 million in Q4 2021 and bottomed at $34357.0 in Q2 2021.
• Historically, Other financing activities has averaged $7.0 million across 3 years, with a median of $147537.5 in 2021.
• On a YoY basis, Other financing activities climbed as much as 177.66% in 2021 and fell as far as 177.66% in 2021.
• Inhibikase Therapeutics' Other financing activities stood at $41.1 million in 2021, then tumbled by 99.89% to $44142.0 in 2022, then surged by 1175.24% to $562915.0 in 2025.
• Business Quant data shows IKT's Other financing activities at $562915.0 in Q4 2025, $250932.0 in Q3 2025, and $44142.0 in Q1 2022.